Company research
Cullinan Therapeutics, Inc.
CIK 1789972Updated Sep 25, 2026
SecurityCGEM · NASDAQ · equity
Name history
Cullinan Oncology, Inc. · through Apr 2, 2024Cullinan Management, Inc. · through Feb 22, 2021Cullinan Oncology, LLC · through Jan 6, 2021
CGEM price & chart
Loading TradingView…
NASDAQ:CGEM on TradingView ↗About the company
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.
In the news
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
144 filing
4 filing
144 filing
Show 5 more recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
144 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 448,374,000Source | 621,824,000Source | 484,182,000Source | 561,117,000Source |
| Property, Plant and Equipment, NetUSD | 421,000Source | 683,000Source | 989,000Source | 1,174,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 88,332,000Source | 83,005,000Source | 98,434,000Source | 156,152,000Source |
| Assets, CurrentUSD | 386,756,000Source | 414,668,000Source | 480,191,000Source | 474,472,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | 619,000Source | 619,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,630,000Source | 1,667,000Source | 2,543,000Source | 4,130,000Source |
| Other Assets, NoncurrentUSD | 297,000Source | 366,000Source | 459,000Source | 459,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 39,644,000Source | 31,496,000Source | 30,287,000Source | 26,088,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 4,000Source | 5,000Source |
| Retained Earnings (Accumulated Deficit)USD | -588,119,000Source | -368,240,000Source | -200,857,000Source | -47,695,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,020,000Source | -133,000Source | -129,000Source | -2,601,000Source |
| Stockholders' Equity Attributable to ParentUSD | 408,730,000Source | 590,328,000Source | 453,703,000Source | 535,029,000Source |
| Additional Paid in Capital, Common StockUSD | 995,823,000Source | 958,695,000Source | 654,685,000Source | 585,320,000Source |
| Liabilities and EquityUSD | 448,374,000Source | 621,824,000Source | 484,182,000Source | 561,117,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 37,741,000Source | 30,647,000Source | 28,137,000Source | 22,498,000Source |
| Operating Lease, Liability, CurrentUSD | 780,000Source | 1,302,000Source | 1,440,000Source | 1,421,000Source |
| Accounts Payable, CurrentUSD | 841,000Source | 1,682,000Source | 2,493,000Source | 2,660,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,903,000Source | 849,000Source | 2,150,000Source | 3,590,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 0Source | 0Source | 192,000Source | 0Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 36,120,000Source | 27,663,000Source | 24,204,000Source | 14,135,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 377,900,000Source | 399,000,000Source | — | — |
| Dividends PayableUSD | 0Source | 0Source | — | — |
| Short-term InvestmentsUSD | 289,564,000Source | 315,972,000Source | 368,633,000Source | 311,140,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -219,879,000Source | -167,575,000Source | -155,101,000Source | 109,195,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 311,000Source | 306,000Source | 310,000Source | 93,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 36,040,000Source | 37,824,000Source | 30,438,000Source | 27,957,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -839,000Source | -812,000Source | -167,000Source | -509,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | 3,000,000Source | 5,400,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -175,750,000Source | -145,303,000Source | -134,275,000Source | -126,664,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 179,989,000Source | -136,314,000Source | 35,806,000Source | 248,975,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 49,000Source | 0Source | 208,000Source | 1,133,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 1,088,000Source | 266,188,000Source | 40,751,000Source | -25,933,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | 32,000Source |
| Income Taxes Paid, NetUSD | -2,970,000Source | -2,274,000Source | -4,433,000Source | 37,801,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 36,040,000Source | 37,824,000Source | 30,438,000Source | 27,957,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 377,900,000Source | 399,000,000Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 300,000Source | 300,000Source | 300,000Source | 100,000Source |
| Dividends PayableUSD | 0Source | 0Source | — | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | 0Source | 77,000Source |
| General and Administrative ExpenseUSD | 54,246,000Source | 54,016,000Source | 42,493,000Source | 40,189,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 117,000Source | -14,122,000Source | 42,121,000Source |
| Investment Income, InterestUSD | 22,212,000Source | 29,660,000Source | 21,627,000Source | 6,611,000Source |
| Net Income (Loss) Attributable to ParentUSD | -219,879,000Source | -167,383,000Source | -153,162,000Source | 111,214,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 0Source | -192,000Source | -1,939,000Source | -2,019,000Source |
| Operating ExpensesUSD | 241,648,000Source | 196,919,000Source | 190,649,000Source | 132,137,000Source |
| Operating Lease, ExpenseUSD | 1,200,000Source | 1,200,000Source | 1,700,000Source | 1,100,000Source |
| Other Nonoperating Income (Expense)USD | -443,000Source | -199,000Source | 239,000Source | 57,000Source |
| Proceeds from Contributions from ParentUSD | — | — | 0Source | 1,153,000Source |
| Proceeds from Issuance of Common StockUSD | 0Source | 262,652,000Source | 38,388,000Source | 6,020,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 0Source |
| Operating Income (Loss)USD | -241,648,000Source | -196,919,000Source | -191,089,000Source | 144,648,000Source |
| Other Nonoperating Income (Expense)USD | -443,000Source | -199,000Source | 239,000Source | 57,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -219,879,000Source | -167,458,000Source | -169,223,000Source | 151,316,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 117,000Source | -14,122,000Source | 42,121,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 0Source | -192,000Source | -1,939,000Source | -2,019,000Source |
| Net Income (Loss) Attributable to ParentUSD | -219,879,000Source | -167,383,000Source | -153,162,000Source | 111,214,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -3.69Source | 2.46Source |
| Earnings Per Share, DilutedUSD per share | — | — | -3.69Source | 2.38Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 41,550,000Source | 45,164,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 41,550,000Source | 46,640,000Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 0Source | 100,000Source | 14,100,000Source | 42,100,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 300,000Source | 300,000Source | 300,000Source | 100,000Source |
| General and Administrative ExpenseUSD | 54,246,000Source | 54,016,000Source | 42,493,000Source | 40,189,000Source |
| Investment Income, InterestUSD | 22,212,000Source | 29,660,000Source | 21,627,000Source | 6,611,000Source |
| Operating ExpensesUSD | 241,648,000Source | 196,919,000Source | 190,649,000Source | 132,137,000Source |
| Operating Lease, ExpenseUSD | 1,200,000Source | 1,200,000Source | 1,700,000Source | 1,100,000Source |
| Research and Development ExpenseUSD | 187,402,000Source | 142,903,000Source | 148,156,000Source | 91,948,000Source |
Filing attachments
cgem-ex99_1.htm · 8-K · 2026-09-24
Exhibit 99.1 Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren’s disease in December CLN-049 (FLT3 TCE) updated data from the Phase 1 dose escalation study in December CAMBRIDGE, Mass. September 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “C…
Read attachment ↗cgem-ex99_1.htm · 8-K · 2026-09-14
EX-99.1 2 cgem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer Results from the Phase 3 REZILIENT3 trial were featured in a Presidential Symposium at WCLC 2026 and demonstrated a statistically significant improvement in progression-free survival in first-line EGFR exon 20 insertion mutation NSCLC at a plan…
Read attachment ↗cgem-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 cgem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer PRINCETON, New Jersey, TOKYO, Japan, CAMBRIDGE, Mass., August 12, 2026 - Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the REZILIENT3 trial, a global …
Read attachment ↗cgem-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 cgem-ex99_1.htm EX-99.1 EX-99.1 Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 Velinotamig (BCMA TCE) multi-dose regimen data in SLE in Q4 2026; Phase 1/2 basket study in autoimmune cytopenias to begin early 2027 CLN-049 (FLT3 TCE) potentially registrational Phase 2 study in R/R AML to begin in Q3 2026 …
Read attachment ↗cgem-ex99_1.htm · 8-K · 2026-06-10
EX-99.1 2 cgem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) CLN-978 data from the first RA multi-dose regimen cohort demonstrated robust efficacy, including clinical remission in a poly-ref…
Read attachment ↗cgem-ex99_1.htm · 8-K · 2026-06-08
EX-99.1 2 cgem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 Deep, dose-dependent B cell depletion observed in peripheral blood and tissue Favorable safety profile with single target doses up to 30 µg…
Read attachment ↗